Navigation Links
Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Date:1/5/2012

DEERFIELD, Ill., Jan. 5, 2012 /PRNewswire/ -- Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.  BAX 855 is based on Baxter's ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] full-length rFVIII molecule and plasma/albumin-free (PAF) manufacturing process.

The Phase I trial is a prospective, open-label study that will assess the safety, tolerability and pharmacokinetics of BAX 855 in previously-treated patients aged 12 years or older with severe hemophilia A.  When used for prophylaxis, Baxter's ADVATE requires patients to infuse every two to three days to reduce the occurrence of bleeding episodes.  This Phase I trial is the first step in assessing whether BAX 855 can be infused less frequently. 

"This trial is designed to provide new insights about our investigational longer-acting FVIII molecule, BAX 855, with the ultimate goal of improving care for patients living with hemophilia A," said Prof. Hartmut J. Ehrlich, M.D., vice president of global research and development in Baxter's BioScience business. "The Phase I results will serve as the foundation for advancing this important program through clinical development and determining whether BAX 855 can offer a treatment regimen requiring fewer infusions than ADVATE."

BAX 855 employs Baxter's proprietary full-length plasma/albumin-free recombinant protein platform that does not contain any human or animal-derived additives. BAX 855 leverages Nektar Therapeutics' (NASDAQ: NKTR) proprietary PEGylation technology, which is designed to extend the duration of activity of proteins and larger molecules.  Baxter and Nektar have a collaboration to develop PEGylated products designed
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hikma Expands its Global Injectables Business Through the Acquisition of Baxter Healthcare Corporations Multi-Source Injectables Business
2. Variation Biotechnologies Names Jeff Baxter CEO
3. Baxter International First Quarter 2009 Financial Results Conference Call
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Halozyme Receives $5.5 Million Payment From Baxter
6. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
7. AmeriCares Presents Power of Partnership Award to Baxter
8. Baxter International Third Quarter 2008 Financial Results Conference Call
9. Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year
10. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
11. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated ... company committed to the fostering and monetization of ... v. VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  ... No. 3:13-cv-03496-M, both in the United States District ... Texas . On November ...
(Date:11/22/2014)... 2014 Prominent academics, leaders of ... on December 3rd at Genetic Rx, a networking ... will take place at the Joseph B. Martin ... discuss the present and future of genetic medicines—including ... gene editing—as well as the treatment of patients ...
(Date:11/22/2014)... MI (PRWEB) November 22, 2014 ... to simulate the proper management of life-like respiratory ... test lung devices . Grand Rapids-based, Michigan Instruments ... to donate two of the respiratory simulation units ... $15,000 each. Grand Valley and Muskegon Community College ...
(Date:11/21/2014)... USA (PRWEB) November 19, 2014 The ... our lives was shared with more than 200 primary ... postgraduate students from the University of Otago Physics Department ... . The Otago students, members of the university’s OSA/SPIE ... Zealand in early September, giving children from small, rural ...
Breaking Biology Technology:Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3
... BETHESDA, Md., Sept. 16 American Capital Ltd. ... 15, it completed the sale of its portfolio company Axygen ... Inc., to Corning Incorporated for approximately $400 million. The ... fee income, from the equity invested by American Capital,s affiliated ...
... , , COLUMBIA, Md., Sept. 16 Martek ... David M. Pernock to its Board of Directors. , ... extensive background in the commercialization of pharmaceutical products, having served from ... (GSK), one of the world,s leading healthcare companies. In his most ...
... HEIDELBERG, Germany, September 16 , ... Drug Targets in Wnt Pathway , ... antagonizes Wnt signalling"** is now available online in,Nature. , ... proteomics,platform was used to identify a small molecule which plays ...
Cached Biology Technology:American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 2American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 4Martek Announces Addition to Its Board of Directors 2Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway 2
(Date:11/15/2014)...  While we may still be a few years away ... Trek" to gain instant access to all that ailed his ... and tablets for monitoring and measuring our health are cropping ... seem a tad Orwellian to some, but a new survey ... technological opportunities into their healthcare regime. These are ...
(Date:11/11/2014)... -- Forensicon, Inc., a Chicago -based digital ... promotion of Yaniv Schiff from Senior Computer ... new role as Director, he will lead company efforts ... and provide leadership within the company,s digital forensics practice ... Schiff joined Forensicon in 2006 and ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... COLLEGE STATION The U.S. Department of Energy has granted more ... fuel source. And if that succeeds within 18 months, almost $2 million ... fast-growing grass species. , ... our country is the leader around the world in terms of energy ...
... fishermen would not give up their livelihood in the face ... University of East Anglia (UEA). A new report, published ... about poverty and adaptation by investigating why fishermen in developing ... Daw from UEA,s School of International Development and the Stockholm ...
... 2012 Aware, Inc. (NASDAQ: AWRE ), a ... today reported financial results for its fourth quarter and year ... fourth quarter of 2011 was $5.9 million, a decrease of ... year. Net income for the fourth quarter of 2011 was ...
Cached Biology News:US Energy Department grants $1.87 million for plant fuel project 2University of East Anglia research reveals why fishermen keep fishing despite dwindling catches 2University of East Anglia research reveals why fishermen keep fishing despite dwindling catches 3Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 2Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 3Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 4Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 5
... Low Speed Shaker ,Product Information ... shaker is a high quality, general purpose shaker ... after the other models in the line, the ... easy-access control panel. Electronic controls are utilized for ...
This modular benchtop laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Options include a work bench, ionizaing bar, and air velocity gauge....
... Ligands\n\nReceptor-related research has long been enabled by ... selected to keep pace with new discoveries. ... and services for receptor research and drug ... you do not find exactly what you ...
... enables sensitive and specific detection of microRNAs ... probes have high binding affinity and discrimination, ... miRNAs. Due to the high binding affinity ... 1/10 the amount of sample is needed ...
Biology Products: